The endocannabinoids present a rich system of central cannabinoid (CB), peripheral cannabinoid (CB), and non-CB receptor-mediated pharmacology that has stimulated research in many fields including memory, weight loss and appetite, neurodegeneration, tumor surveillance, analgesia, and inflammation. Arachidoyl ethanolamide is one of the saturated fatty acyl ethanolamides devoid of classical (CB/CB) activity. Arachidoyl ethanolamide does not bind to the murine CB receptor and does not compete with anandamide as a substrate for the endocannabinoid hydrolytic enzyme fatty acid amide hydrolase. Non-CB receptor-mediated pharmacology of the saturated ethanolamides is still being elucidated.